These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 7639232

  • 1. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
    Avner DL, Movva R, Nelson KJ, McFarland M, Berry W, Erfling W.
    Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
    [Abstract] [Full Text] [Related]

  • 2. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
    Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P.
    Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM.
    Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
    [Abstract] [Full Text] [Related]

  • 4. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A, Dattilo M.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [Abstract] [Full Text] [Related]

  • 5. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M.
    Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S, Italian Lansoprazole Study Group.
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [Abstract] [Full Text] [Related]

  • 10. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
    Arroyo Villarino MT, Lanas Arbeloa A, Esteva Díaz F, Ortego Fernández de Retana J, Sainz Samitier R.
    Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
    Swarbrick ET, Gough AL, Foster CS, Christian J, Garrett AD, Langworthy CH.
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):431-8. PubMed ID: 8804870
    [Abstract] [Full Text] [Related]

  • 13. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J.
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [Abstract] [Full Text] [Related]

  • 14. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
    Kushner PR, Snoddy AM, Gilderman L, Peura DA.
    Postgrad Med; 2009 Jul; 121(4):67-75. PubMed ID: 19641272
    [Abstract] [Full Text] [Related]

  • 15. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, Jennings DE.
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [Abstract] [Full Text] [Related]

  • 16. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL, Huang B, Amer F, Christopoulos NG.
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [Abstract] [Full Text] [Related]

  • 17. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
    Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, Goldstein JL.
    Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
    [Abstract] [Full Text] [Related]

  • 18. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
    Kovacs TO, Campbell D, Haber M, Rose P, Jennings DE, Richter J.
    Dig Dis Sci; 1998 Apr; 43(4):779-85. PubMed ID: 9558034
    [Abstract] [Full Text] [Related]

  • 19. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E.
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [Abstract] [Full Text] [Related]

  • 20. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N.
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.